Breast Cancer Research This program is focused upon making improvements in breast cancer patient regimens and outcomes, using an interdisciplinary approach. Our program hopes to achieve this goal by utilizing an improved understanding of the distinct biology of the intrinsic subtypes of breast cancer and breast cancer heterogeneity obtained through tissue-based studies, with additional biomarker discovery and validation, risk factor appraisal, and drug development, which lead to new therapeutic trials and population-based studies. Specifically, our strategic goals are: 1) basic and epidemiologic science discovery integrated with our existing understanding of the intrinsic breast cancer subtypes, 2) technological advances in imaging and therapy, 3) mouse models testing of promising therapeutic approaches in models representing the known biological subtypes, and 4) tissue-based discovery and clinical research algorithms for rational drug/combination studies with bidirectional strategies of containing embedded correlative/research biopsy studies. The Breast program is well suited to foster translation of basic science findings Into the clinic and back again because it is heavily integrated into a very active multidisciplinary clinical and clinical-translational operation, n addition, this program is seamlessly integrated with our mature breast cancer SPORE infrastructure that includes clinicians, epidemiologists, and laboratory scientists. Highlights of research by program investigators include development of genetically engineered mouse models representing many of tine intrinsic subtypes allowing subtype-specific therapeutic strategies to be tested in the mouse phase I unit (Perou, Sharpless), the development of anotechnology-based and other novel imaging that can be applied to both small animal and human breast cancers (Zhou, Pisano), and the design and execution of clinical trials using novel regimens and trial designs (Carey, Anders);the clinical focus remains on the manage of subtype-specific prospective clinical trials with targeted agents and embedded correlative analysis of molecular signatures and cross-trial validations. Substantial progress in understanding the risk factors and molecular biology of specific intrinsic subtypes has come from collaborations between faculty from the schools of Medicine, Public Health, and Genetics, including the first identification of the association of basal-like breast cancer with African-American women (Carey, Perou, MiDikan). The population-based Carolina Breast Cancer Study III is integral to this program and is examining subtype-specific risk factors and outcomes with a focus upon African-American women. Complementary studies are examining epigenetic and microenvironmental influences (Troester, Swift-Scanlan) that should address the """"""""soil"""""""" contributions to these risks, and a new program in geriatric oncology is focusing upon molecular correlates of breast tumor and host response to therapy (Muss, Sharpless). The Program consists of 24 members from five different schools and clinicians from five different disciplines. In 2009, Breast Research Program members held 56 grants and $12.3M (total cost) in annual extramural funding, including 24 grants and $7.4M (total costs) from the NCI.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-38
Application #
8594139
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$151,590
Indirect Cost
$66,181
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Knott, Simon R V; Wagenblast, Elvin; Khan, Showkhin et al. (2018) Erratum: Asparagine bioavailability governs metastasis in a model of breast cancer. Nature 556:135
Anderson, Chelsea; Smitherman, Andrew B; Nichols, Hazel B (2018) Conditional relative survival among long-term survivors of adolescent and young adult cancers. Cancer 124:3037-3043
Liu, Meng-Xi; Jin, Lei; Sun, Si-Jia et al. (2018) Metabolic reprogramming by PCK1 promotes TCA cataplerosis, oxidative stress and apoptosis in liver cancer cells and suppresses hepatocellular carcinoma. Oncogene 37:1637-1653
Curtis 2nd, Alan D; Jensen, Kara; Van Rompay, Koen K A et al. (2018) A simultaneous oral and intramuscular prime/sublingual boost with a DNA/Modified Vaccinia Ankara viral vector-based vaccine induces simian immunodeficiency virus-specific systemic and mucosal immune responses in juvenile rhesus macaques. J Med Primatol 47:288-297
Williams, Lindsay A; Nichols, Hazel B; Hoadley, Katherine A et al. (2018) Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study. Cancer Causes Control 29:25-32
Amunugama, Ravindra; Willcox, Smaranda; Wu, R Alex et al. (2018) Replication Fork Reversal during DNA Interstrand Crosslink Repair Requires CMG Unloading. Cell Rep 23:3419-3428
Little, Michael S; Pellock, Samuel J; Walton, William G et al. (2018) Structural basis for the regulation of ?-glucuronidase expression by human gut Enterobacteriaceae. Proc Natl Acad Sci U S A 115:E152-E161
Sin, Sang-Hoon; Eason, Anthony B; Bigi, Rachele et al. (2018) Kaposi's Sarcoma-Associated Herpesvirus Latency Locus Renders B Cells Hyperresponsive to Secondary Infections. J Virol 92:
Dellon, Evan S; Selitsky, Sara R; Genta, Robert M et al. (2018) Gene expression-phenotype associations in adults with eosinophilic esophagitis. Dig Liver Dis 50:804-811
Rojas, Juan D; Lin, Fanglue; Chiang, Yun-Chen et al. (2018) Ultrasound Molecular Imaging of VEGFR-2 in Clear-Cell Renal Cell Carcinoma Tracks Disease Response to Antiangiogenic and Notch-Inhibition Therapy. Theranostics 8:141-155

Showing the most recent 10 out of 1525 publications